Uppdatering inför ordinarie teckningsperiod för teckningsoptioner TO5B
Ordinarie teckningsperiod för teckningsoptioner av serie TO5B är mellan 20 – 31...
Hamlet BioPharma går nu vidare med förhandlingar om villkor och ramar för slutförande av läkemedelsutveckling och kommersialisering av Alpha1H Tillsam...
Hamlet BioPharma, a pharmaceutical company specializing in the development of novel treatments for cancer and infectious diseases, today announces reg...
Den digitala analysplattformen Briefglance har uppmärksammat Hamlet BioPharma och samarbetet med Universitetet i Iowa kring utvecklingen av Alpha1H fö...
Hamlet BioPharma today announces the successful release of the Phase III quality batch of Alpha1H for use in clinical trials of bladder cancer in Euro...
Hamlet BioPharma invites you to our monthly investors’ meeting to be held on the 30th of June 2026, at 12:00.
Please click on the link below to partic...
Hamlet BioPharma AB (publ) today announced the signing of a clinical trial agreement with the University of Iowa, one of the leading U.S. centers for ...
Hamlet BioPharma AB (publ) today conducted a pre-initiation visit at the Department of Urology at Charles University, Prague, led by Professor Marek B...
The Journal of Infectious Diseases publishes the paper “Targeting the disease response with NlpD and LytM for effective non-antibiotic treatment of ur...
